TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07702955: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Single-Agent KGX105 in Participants With Locally Advanced or Metastatic Solid Tumors

Sponsor: Kangabio AUSTRALIA LTD PTY · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 85 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07702955 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07702955 Rescue Dossier →